What Ferranina Treats: Main Uses and Benefits

Ferranina (Iron Hydroxide Polymaltose), as an antianemic preparation, is generally used to address the systemic manifestations of iron deficiency in its various stages. Iron is used to treat or prevent anemia when the amount of iron taken in from the diet is not enough to meet the body's requirements. The primary therapeutic purpose is iron replenishment, which assists in addressing the systemic imbalance within the body.

The treatment is commonly applied across conditions where additional symptomatic support is needed, primarily Iron Deficiency Anemia (IDA) and latent iron deficiency. It is also relevant for managing states of chronic loss, such as those caused by heavy menstrual bleeding, or periods of high demand, like pregnancy and lactation. By providing a stable source of iron, Ferranina helps manage the profound systemic fatigue and chronic weakness—symptoms that interfere with daily functioning—that characterize low iron status. This supportive use provides relief when symptoms interfere with routine activities and supports general well-being during symptomatic phases.

Quick Fact: Support for Iron Deficiency Symptoms
Symptom Category	Symptoms related to systemic imbalance
Focus of Benefit	Contributes to improved comfort and stamina
Context	Chronic weakness and impaired daily functioning

Regulatory References

1. NIH MedlinePlus guidance on iron supplements

Eligibility for Ferranina (Iron Hydroxide Polymaltose)

The official eligibility criteria for Ferranina are based on a patient's underlying condition and physiological state, as defined in regulatory labeling.

---

Contraindications

Ferranina must not be used in patients with an absolute contraindication, which includes conditions such as:

• Iron Overload Syndromes (e.g., Haemochromatosis or Haemosiderosis).
• Anaemia Not Caused by Iron Deficiency (e.g., Haemolytic Anaemia or Megaloblastic Anaemia due to Vitamin B12 deficiency).
• Iron Utilization Disorders (e.g., Sideroblastic Anaemia).
• Known Hypersensitivity to the active substance or excipients.

---

Specific Population Rules

Population Group	Regulatory Status	Restriction/Limitation
Age (Adults/Adolescents)	Use is established	Approved for treatment of iron deficiency.
Age (Pediatric)	Use is established	Eligibility depends on formulation; certain tablets may be not recommended for children 12 and under.
Pregnancy	Use permitted	Generally advised after the first trimester when iron deficiency is documented.
Lactation	Use permitted	Permitted when iron deficiency is present.
Organ Function	Restricted use	Contraindicated in severe liver and kidney diseases.

These rules ensure the medicine is directed only towards populations where iron supplementation is clinically appropriate and safe, according to governmental health authorities.

Interactions with other medicines and products

The regulatory profile of Ferranina (Iron Hydroxide Polymaltose) structures its interaction data based on the non-ionic, complex-bound nature of its active ingredient, which results in a low potential for certain common interactions seen with simple iron salts.

Documented Interaction Patterns

Interaction Type	Official Regulatory Statement
With Ionic Binders (Tetracyclines, Antacids)	Ionic interaction is unlikely to occur with co-administered drugs like Tetracyclines and Antacids as a result of the complex structure.
With Food Components	Ionic interaction with common food components (e.g., phytin, oxalates) is not expected due to the stability of the compound.
With Other Iron Formulations	Co-administration with intravenous iron formulations must be avoided, as this combination significantly inhibits the absorption of the oral iron component.

---

Timing-Based Separation

A mandatory timing separation is required when co-administering this product with certain mineral preparations. Administration of Ferranina and calcium-containing preparations must be separated by at least 2 hours to mitigate the potential for reduced iron absorption. The official documented interaction profile for Iron Hydroxide Polymaltose does not list formal contraindications for other drug classes, and no metabolic or transporter-based interactions are explicitly stated in the regulatory labeling.

Ferranina, a stable ferric iron complex, is designed to replenish functional and storage iron compartments. Following administration, the complex is primarily taken up via endocytosis by macrophages of the reticuloendothelial system (RES), particularly within the liver, spleen, and bone marrow.

Inside the macrophage endolysosome, the complex undergoes degradation in the acidic environment, releasing ferric iron (Fe^3+). This released iron is then reduced to the ferrous state (Fe^2+) and exported from the cell via the iron exporter, ferroportin (FPN1).

In the systemic circulation, the exported iron is rapidly oxidized back to Fe^3+ by ceruloplasmin and then complexed with transferrin (Tf), forming diferric transferrin. This Tf-bound iron is transported to target tissues, including the bone marrow, where it is internalized by erythroid precursor cells via the transferrin receptor (TfR1). The internalized iron is utilized in the mitochondria for the final molecular synthesis of heme, an essential prosthetic group for hemoglobin. Iron not immediately used is sequestered intracellularly for storage as ferritin and hemosiderin. This controlled iron delivery modulates systemic iron homeostasis and supports the cellular process of erythropoiesis.

How to Use Ferranina

The usage of Ferranina (Iron Hydroxide Polymaltose) follows specific guidelines focusing strictly on administration route, dosing, and duration principles.

Administration and Dosing

The medicine is intended for oral administration only, utilizing forms such as tablets, capsules, syrups, or drops. The daily dosage for adults with manifest iron deficiency or anemia typically ranges from 100 mg to 200 mg of elemental iron. For addressing latent iron deficiency, a lower daily dose of 100 mg is often specified. The total daily dose may be taken once or divided into separate doses.

Administration should occur with a meal or immediately following food intake, a practice intended to support better patient tolerance. Liquid forms, such as drops or syrup, can be mixed with fruit or vegetable juices or infant formula just prior to being taken.

Duration and Population Rules

Treatment duration is not fixed but is based on the principle of replenishing the body's iron stores. Use must be continued for a period sufficient to normalize iron reserves, which typically means extending administration for at least one additional month after the clinical signs of deficiency have been addressed.

For specific populations, older adults generally do not require any dose adjustment and can use standard adult regimens. In contrast, pediatric dosing is calculated according to body weight. Usage instructions also note that the medicine is not applicable for use in cases of severe liver or kidney disease.

Research evidence / Overview of Studies for Ferranina

Evidence for Use in Iron Deficiency Anemia (IDA) in Adults

The research landscape includes studies such as Randomized Controlled Trials (RCTs) and subsequent Meta-Analyses. These studies evaluated changes in core hematological parameters, such as Hemoglobin (Hb) levels and red blood cell metrics. In these research scenarios, the medicine was observed in comparison to standard, traditional iron salts, like ferrous sulfate.

Research highlights that the outcomes monitored during the study period showed patterns related to changes in Hemoglobin concentration, which is a key physiological measure. The trials also examined changes in iron storage, measured by Serum Ferritin (SF) levels. Data show patterns related to changes in iron stores, but findings were mixed when directly evaluating the differences against traditional iron salts.

Evidence for Use in Iron Deficiency Anemia During Pregnancy

Research examined the use of Iron Hydroxide Polymaltose in pregnant individuals diagnosed with mild to moderate Iron Deficiency Anemia. The evidence includes Comparative Trials that monitored changes in maternal blood parameters. Studies evaluated outcomes related to systemic or functional imbalance, specifically looking for changes in Hemoglobin concentration and iron storage markers.

Findings indicate that patterns related to changes in Hemoglobin were observed in the studied populations during the short-term treatment period. Research provides context on the outcomes monitored in iron storage levels over the observed time intervals. However, the available evidence is limited by its focus on the initial, short-term measurement of blood parameters.

Long-Term Evidence and Follow-up Duration

The majority of clinical trials conducted on Iron Hydroxide Polymaltose for anemia biomarker changes are characterized by short-term follow-up durations. The research explored short-term changes in biomarkers and typically monitored responses over defined time intervals, usually concluding treatment and observation between 8 and 13 weeks.

The long-term evidence is not fully characterized, and data are still emerging. There is limited information for long-term outcomes regarding the durability of the iron status changes observed during the study phase.

Key Studies & References

1. Comparison of efficacy and tolerability of iron polymaltose complex with ferrous sulphate in treatment of children with iron deficiency anemia (2022)

Common questions about Ferranina (FAQ)

Q: What is the main difference between Ferranina and other similar iron supplements?

According to official product information, Ferranina is a non-ionic iron complex with a stable carbohydrate structure. This chemical design is intended to prevent the release of free iron ions in the digestive system. Studies indicate this may help minimize the gastrointestinal irritation that is often associated with older forms of iron salts.

Q: Does the time of day I take Ferranina matter?

Regulatory texts state that the non-ionic nature of this iron complex allows for flexibility in timing. Official usage instructions describe administration occurring with a meal or immediately following food intake. Taking the preparation alongside food is a general recommendation intended to support better tolerance.

Q: Why do some people use Ferranina even if they aren't diagnosed with severe anemia?

Official guidelines state the product is indicated for the treatment of various forms of iron deficiency. This includes latent iron deficiency (when the body's iron stores are low but anemia has not fully developed) as well as manifest iron deficiency, which is anemia.

Q: Is Ferranina generally well-tolerated compared to other iron treatments?

Clinical studies that compared this preparation to traditional iron salts (such as ferrous sulfate) indicated patterns of a lower incidence of adverse gastrointestinal side effects. These effects include common issues like nausea, abdominal discomfort, and constipation.

Q: Can I take vitamins alongside Ferranina?

Official regulatory documents specify that a timing separation of at least 2 hours is used when taking this product with calcium-containing preparations. The official interaction profile does not explicitly list formal metabolic interactions for most other common vitamin supplements.

Q: How is Ferranina different from the iron I get in my food?

This medicine contains a synthetic macromolecular complex of iron that is structurally designed to resemble the body's natural iron storage protein, ferritin. This formulation allows for its absorption to be highly controlled and regulated, ensuring iron uptake occurs primarily through active transport pathways.

Q: If I feel better, can I stop taking Ferranina?

The duration of treatment is based on the goal of fully replenishing the body's iron reserves, not just resolving physical symptoms. Regulatory texts describe that use is continued for a period sufficient to normalize these reserves, which often means continuing for at least one additional month after clinical signs have resolved.

Q: Is Ferranina effective for all types of iron deficiency?

Regulatory documents state that this preparation is intended for iron deficiency only. The medicine is contraindicated, meaning it is generally not used for treating any type of anaemia not caused by iron deficiency, such as those related to Vitamin B12 deficiency or certain blood disorders.

Q: Is Ferranina a prescription drug or can I buy it over the counter?

The regulatory classification of Ferranina can vary by jurisdiction. In some regions, official labeling classifies the iron polymaltose complex as a Human Prescription Drug product.

Q: How quickly should I expect to see an effect from taking Ferranina?

Pharmacokinetic studies have provided context on the timeline of the medicine's activity. Evidence indicates that the peak incorporation of the iron from the preparation into the blood's red cells typically occurs approximately 2 to 3 weeks following the start of administration.

Q: What should I do if I miss a scheduled dose of Ferranina?

General regulatory guidance for oral iron preparations typically describes taking the missed dose as soon as it is remembered. If the time is almost right for the next scheduled dose, only the usual single dose is described as being taken. Double dosing is not advised.

Q: Does Ferranina interact with common headache or pain relievers?

Chemical and laboratory studies have investigated the potential for interaction between this unique iron complex and common medications. Evidence indicates that the structure of the iron complex means it does not interact with the active ingredients of common pain relievers such as acetylsalicylic acid (aspirin) or acetaminophen (paracetamol).

Q: Do any official warnings exist about operating machinery while using Ferranina?

Official regulatory documents, such as the Summary of Product Characteristics (SmPC), state that the administration of this medicine does not affect the ability to drive or operate machinery.

How to Store and Dispose of Ferranina (Iron Hydroxide Polymaltose)

Storage and disposal instructions for Ferranina are officially defined to maintain product stability and ensure safety.

---

Storage Requirements

Ferranina must be stored at Controlled Room Temperature, generally between 20 C and 25 C. The product requires protection from both light and moisture and must be kept in its original, tightly closed container.

• Mandatory Restrictions: The medicine must not be frozen.
• Stability Constraint: Oral liquid formulations must be discarded after a specific period (e.g., 3 to 6 months) following the initial opening.
• Child Safety: The product must be stored out of the sight and reach of children.

---

Disposal Instructions

Official regulations require that unused or expired Ferranina must not be disposed of via household trash or wastewater. The proper method is to return the unwanted medicine to a pharmacist or an official collection program for environmentally compliant pharmaceutical waste management.